Company news

Arcturus Therapeutics Holdings Inc. news in 2023

Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2023, newest first.

View company

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

December 20, 2023

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 3, 2023

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

November 27, 2023

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

November 26, 2023

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis

November 26, 2023

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

November 13, 2023

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023

October 24, 2023

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government

October 3, 2023

Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis

September 25, 2023

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

September 18, 2023

Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19

September 4, 2023

Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government

August 13, 2023

Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress

August 6, 2023

Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

July 23, 2023

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

May 31, 2023

Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress

May 8, 2023

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023

April 25, 2023

Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress

March 27, 2023

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023

March 6, 2023

Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis

January 30, 2023

Calls in 2023

Decks in 2023